Skip to main content
. 2021 Jan 8;10:585551. doi: 10.3389/fonc.2020.585551

Figure 2.

Figure 2

Elevated MYBL2 mRNA expression is a strong predictor of poor outcomes in lung adenocarcinoma. (A) Kaplan-Meier analyses demonstrate that patients with MYBL2 High tumors have significantly poorer OS rates, compared to patients with MYBL2 Low tumors (log-rank p = 2.2e–3, ΔMMS = 49.6 months). (B) Kaplan-Meier analyses indicate that MYBL2 High tumors are significantly more likely to recur, compared to MYBL2 Low tumors (log-rank p = 2.4e–2, ΔMMS = 19.8 months). (C) Kaplan-Meier survival analyses confirm that patients with MYBL2 High have significantly poorer OS outcomes, compared to MYBL2 Low when validated in an independent cohort provided by ORIEN (log-rank p = 3.1e–3, ΔMMS = 55.3 months). (D) Kaplan-Meier analyses confirm that ORIEN MYBL2 High tumors are significantly more likely to recur, compared to ORIEN MYBL2 Low tumors (log-rank p = 1.5e–2). (E) OS Kaplan-Meier analysis reveals that MYBL2 is a strong marker of patient outcomes in Stage III/IV disease (log-rank p = 7.9e–3, ΔMMS = 61.2 months).